Amarin Corp Plc (AMRN)

[ziploc_1]

Rose...Since the Brave test was started 5 years ago, I have a feeling it will end on schedule in Jan 2023...and I agree with sleven that it is an invasive study (e.g. it includes serial spinal taps) and it would have been stopped by now if there was no evidence of effectiveness....The following is info on the study...

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults

Actual Study Start Date : June 8, 2017
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : January 31, 2023

Even though BRAVE is a small study...considering the severity of Alzheimers and the safety profile of Vascepa, IMO the FDA would react positively to a statistically significant result.